Энциклопедия женского здоровья. Контрацепция без последствий - читать онлайн книгу. Автор: Оксана Богдашевская cтр.№ 37

21. Heit J., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study //Ann. Intern. Med. – 2005. – Vol. 143 (10). – Р. 697–706.

22. Carrie Armstrong ACOG Guidelines on Noncontraceptive Uses of Hormonal Contraceptives // Am. Fam. Physician. 2010. Aug 1. Vol. 82 (3). P. 288–295.

23. Curtis K.M., Tepper N.K., Jatlaoui T.C. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. // MMWR Recomm. Rep. 2016. Vol. 65 (3). P.1. [Epub 2016 Jul 29] [PMID 27467196].

24. Calhoun A.H. Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? // Headache. 2017. Vol. 57 (2). P. 184. [Epub 2016 Oct 24] [PMID 27774589].

25. Chürks M. et al. Migraine and cardiovascular disease: systematic review and meta-analysis // BMJ. 2009. Vol. 339. P. 657–665. [PMID: 19861375].

26. Tepper N.K., Whiteman M.K., Zapata L.B. et al. Safety of hormonal contraceptives among women with migraine: A systematic review. //Contraception. 2016. Vol. 94 (6). P. 630–640. [PMID 27153744].

27. Edlow A.G., Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. // Rev. Obstet. Gynecol. 2010. Vol. 3 (2). P. 55–65. [PMID: 20842283].

28. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review./Eur J Contracept Reprod Health Care. 2016;21(5):347. Epub 2016 Aug 15.

29. Wiréhn AB, Foldemo A, Josefsson A et al. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study./ Eur J Contracept Reprod Health Care. 2010;15(1):41.

30. Skovlund CW, Mørch LS, Kessing LV, LidegaardØ. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016;73(11):1154.

31. Harlow BL, Wise LA, Otto MW et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles./ Arch Gen Psychiatry. 2003 Jan;60(1):29–36.

32. Joffe H, Cohen LS, Harlow BL Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration./ Am J Obstet Gynecol. 2003 Dec;189(6):1523-30.

33. Toffol E, Heikinheimo O, Koponen P et al. Hormonal contraception and mental health: results of a population-based study./ Hum Reprod. 2011 Nov;26(11):3085-93. Epub 2011 Aug 12.

34. Keyes KM, Cheslack-Postava K, Westhoff C et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States./ Am J Epidemiol. 2013 Nov;178(9):1378-88. Epub 2013 Sep 15.

35. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016; 73(11):1154.

36. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Apr 1;175(4):336–342. Epub 2017 Nov 17.

37. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception./N Engl J Med. 2012 Jun 14;366(24):2257-66.

38. Berlin I, Aubin HJ, Thomas D. Comment on the Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Jul 1;175(7):683.

39. Heinemann L. A., Thiel C., Assmann A., Möhner S. Frequency and reasons for switching/stopping use of oral contraceptives. Results of the German Cohort Study on Women Health // Zentralbl. Gynakol. 2001. Vol. 123. N 10. P. 568–577.

40. Burrows L.J., Basha M., Goldstein A.T.The effects of hormonal contraceptives on female sexuality: a review. J Sex Med 2012 Sep 12;9 (9):2213–23. Epub 2012 Jul 12.

41. Boozalis A, Tutlam NT, Chrisman Robbins C. Sexual Desire and Hormonal Contraception // Obstet Gynecol. 2016 Mar;127 (3): 563-72.

42. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review./ Eur J Contracept Reprod Health Care. 2013 Feb;18 (1):27–43.

43. Zethraeus N, Dreber A, Ranehill E. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial.// J Clin Endocrinol Metab. 2016 Nov;101(11):4046–4053. Epub 2016 Aug 15.

44. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.// J Med Assoc Thai. 2006;89 Suppl 4:S17.

45. Bancroft J, Davidson DW, Warner P. Androgens and sexual behaviour in women using oral contraceptives.// Clin Endocrinol (Oxf). 1980;12(4):327.

46. Di Carlo С., Gargano V., De Rosa N., Antonio Tommaselli G. A. et al. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age // Gynecol. Endocrinol. 2014. Vol. 30. N 12. P. 925–928.

47. Goldstein I.et al.Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review / Mayo Clinic Proceedings, Volume 92, Issue 1, 114–128.

48. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users oral contraceptives: cohort data from the Royal College of General Practitioners oral contraception study. BMJ 2007; 335: 651.

49. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers [published online January 18, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4942.

50. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(11):1931–1943.

51. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncology 2015; 16(9):1061–1070.

52. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.// J Reprod Med. 1996; 41(5 Suppl):428.

53. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.// J Reprod Med. 1996; 41(5 Suppl):419.

54. Montz FJ, Bristow RE, Bovicelli A. et al. Intrauterine progesterone treatment of early endometrial cancer.// Am J Obstet Gynecol. 2002; 186(4):651.

55. Soini T, Hurskainen R, Grénman S. et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.// Obstet Gynecol. 2014 Aug;124(2 Pt 1):292-9.

56. Jareid M, Thalabard JC, Aarflot M. et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study // Gynecol Oncol. 2018;149(1):127. Epub 2018 Mar 2.